[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fasY9nCMZD7ZaEWx14lwi9lpybgX7ITFsoDvk8Vuz_m4":8,"$fXe1RO2gqQnxlDQ1X_Anqq_-GmLJHokeZQZi5iRPgRv8":55,"$frf2rRMDwR2oJp_77xA4n2XlFErK6aUZ2logs-NQXSOQ":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48753,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"卵巢癌复发治疗：了解紫杉醇、卡铂和贝伐珠单抗","","https://ystcdn.venuertc.com/venue/AI/97aafc06-0e21-4d26-82d5-d08b8e44395c.jpg","\u003Cdiv class=\"drug-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌复发治疗：了解紫杉醇、卡铂和贝伐珠单抗\u003C/h1>\n  \u003Cdiv class=\"drug-material-summary\">\n    \u003Cspan class=\"emoji\">💊\u003C/span>\n    \u003Cp>\n      谈到化疗药物，紫杉醇、卡铂和贝伐珠单抗常常同台登场，被广泛用于多种治疗方案中。每种药物都各有特点，合理使用能够提升疗效，但稍有差池也可能带来不必要的副作用。本文将详细解析这三种药物各自的成分、给药方法、用药注意事项、副反应管控等6个关键细节，帮助您用得放心、用得明白。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 紫杉醇、卡铂、贝伐珠单抗：成分与剂型全梳理 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #eaf6fa 0%, #f9fafb 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品成分和剂型全梳理 🌱\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\u003Cb>紫杉醇（Paclitaxel）\u003C/b>：天然来源抗肿瘤药，主要以注射剂（针剂）形式应用，常见规格有30mg、100mg/瓶等。\u003C/li>\n      \u003Cli>\u003Cb>卡铂（Carboplatin）\u003C/b>：铂类金属化合物，制剂为无色或淡黄色注射液，规格常为50mg、150mg、450mg/瓶。\u003C/li>\n      \u003Cli>\u003Cb>贝伐珠单抗（Bevacizumab）\u003C/b>：人源化单克隆抗体，属于靶向抗肿瘤药物，提供注射用浓缩液，一般规格为100mg/4ml和400mg/16ml。\u003C/li>\n      \u003Cli>这三种药品均为静脉注射制剂，需经专业人员操作，不适合自行给药。\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 02 主要作用机制简单说清 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #f5edea 0%, #fcf8f6 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 主要作用机制解读 🔬\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\u003Cb>紫杉醇：\u003C/b>作用于细胞分裂、阻断有丝分裂进程，让异常细胞停止复制。\u003C/li>\n      \u003Cli>\u003Cb>卡铂：\u003C/b>通过破坏细胞DNA结构，抑制其复制能力，减少异常细胞数量。\u003C/li>\n      \u003Cli>\u003Cb>贝伐珠单抗：\u003C/b>抑制新生血管的形成，\"断粮\"机制有效切断异常细胞供养。\u003C/li>\n      \u003Cli>上述作用机制决定了各药物的使用优势，但也伴随特定毒性风险，需要区分对待。\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 03 正确用药方法与给药流程 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #eefaf1 0%, #f8fcfa 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 正确用药方法与给药流程 ⏰\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">紫杉醇\u003C/span>：标准剂量约为每平方米175mg，常规定时静脉滴注，单次给药时间一般为3小时，疗程间隔21天左右。实际剂量须由医师结合体表面积及个体耐受性调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">卡铂\u003C/span>：以AUC（药物曲线下面积）公式计算，常见AUC值在5~6，每3-4周静脉滴注一次，输注时间至少30-60分钟。剂量增强或减量由肾功能决定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">贝伐珠单抗\u003C/span>：建议首剂为15mg/kg体重，静脉缓慢输注90分钟。后续若耐受良好，每次可缩短至60分钟，再下调至30分钟。给药周期一般为2-3周一次。\n      \u003C/li>\n      \u003Cli>\n        💡 \u003Cb>正确做法：\u003C/b>上述药物应按医嘱排程，严格监测不良反应，每次应用均需配合专科护士和医生操作。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-tip\">\n      \u003Cspan class=\"emoji\">📔\u003C/span> \u003Cb>实际案例：\u003C/b>\n      有一位44岁女性患者使用此三种药物序贯化疗，整个周期严格遵循剂量调配及间隔，未自行调整频率或剂量，从而有效避免了急性毒性反应。 \n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 用药禁忌与特殊风险人群 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #f6f9f0 0%, #fafcf9 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 用药禁忌和特殊风险人群 🛑\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">紫杉醇：\u003C/span> 严禁对药物成分或聚氧乙烯蓖麻油高度过敏者使用，孕妇及哺乳期妇女禁用，严重肝功能不全者应慎用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">卡铂：\u003C/span> 对铂类药物过敏者绝对禁用，重度肾功能衰竭或骨髓抑制显著者不建议应用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">贝伐珠单抗：\u003C/span> 活动性出血、高危消化道穿孔患者及严重未控高血压者避免使用。妊娠和哺乳期女性需谨慎权衡利弊。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>特别提醒：\u003C/b> 有严重感染、未控制糖尿病或凝血异常问题的患者，三药使用前均应充分评估风险。\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 05 药物之间及与其他药品的相互作用 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #e2ecf8 0%, #fafcff 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用 & 用药搭配须知 ⚠️\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">紫杉醇：\u003C/span> 遇到酮康唑、西咪替丁等CYP3A4酶抑制剂时，体内浓度可升高，可能加重毒副作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">卡铂：\u003C/span> 遇到高剂量利尿剂时，肾毒性风险增加。与其他骨髓抑制药物合用时，需密切监控血象。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">贝伐珠单抗：\u003C/span> 配合华法林、阿司匹林等抗凝药物，有引发致命性出血风险。多种靶向药联用时有累加毒性。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b> 用药期间如需同时服用上述药物，应主动告知医生，避免自行增减药物；严格遵医嘱核查药物名单。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 06 常见不良反应及处理方法 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #faf3ed 0%, #fdf8f2 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应和识别处理 👀\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">紫杉醇：\u003C/span> 约60%-80%可能出现白细胞下降、周围神经异常、脱发等。可配合升白针、对症药物处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">卡铂：\u003C/span> 恶心呕吐较常见，可达70%，按需配合止吐药使用。个别患者出现肾损伤、耳鸣或听力下降，需定期复查肾功能、听力。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">贝伐珠单抗：\u003C/span> 近5%-15%人群发生高血压、蛋白尿、消化道穿孔等，遇到异常腹痛或极度乏力时需及时就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b> 任何出现持续发热、严重呕吐、皮肤瘙痒红斑等反应，应立刻报告医护团队，不部署自行治疗。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-tip\">\n      \u003Cspan class=\"emoji\">🔎\u003C/span> \u003Cb>实际经验：\u003C/b>\n      曾有患者使用卡铂时因未提及正在服用降压药，致副作用加重。多药叠加管理不可忽略。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存、有效期与药品使用安全 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #e3f3e4 0%, #fbfcfa 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存要求与用药安全 🗄️\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-highlight\">紫杉醇、卡铂、贝伐珠单抗\u003C/span>均需冷藏保存（2～8℃），避免冷冻和阳光直射。开封后溶液不宜长时间暴露，应在规定时间内用完。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>过期药物\u003C/b>：绝对禁止继续使用，应交由医院或药店回收处理，严禁自行倾倒或丢弃。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b> 每次用药前必须核验药品外观、批号和有效期，发现混浊、变色等问题立即拒用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-tip\">\u003Cspan class=\"emoji\">🚮\u003C/span> 过期和变质药品切勿随意丢弃，避免被误服或污染环境。\u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 漏服、过量与紧急处理方案 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #fff9ec 0%, #fdfbf8 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服、过量及应对 ✅\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cb>漏服情况：\u003C/b> 紫杉醇、卡铂、贝伐珠单抗均属于临床集中注射，错过疗程应第一时间联系主治医生，不可擅自补药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>过量风险：\u003C/b> 一次性注入剂量过大，会引起严重骨髓抑制、肾损伤及中枢神经异常，必须立即送医抢救。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b> 若发现或怀疑用量异常，记录下已用剂量信息，携带药品包装即时就医。不可期待体内\"自动代谢清除\"。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003C!-- 09 特殊人群用药调整规范 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #f9f0f5 0%, #fcfafb 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 特殊人群用药调整规范 🧑‍⚕️\u003C/h2>\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cb>老年人：\u003C/b> 60岁以上者效果和耐受性个体差异大，特别是紫杉醇和卡铂，剂量常下调起始，合并用药的可能更高，建议每次使用前都做评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能减退：\u003C/b> 肝功能障碍者避免紫杉醇，肾功能减退慎用卡铂。贝伐珠单抗多由主治医生结合多项指标决定是否继续用药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>孕妇、哺乳期妇女：\u003C/b> 三药均应避免使用，若有特殊用药指征需权衡风险与收益决策，由医生专门指导。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-tip\">\n      \u003Cspan class=\"emoji\">👵\u003C/span> 临床上，一位老年患者使用紫杉醇时因剂量下调，骨髓抑制副作用降低并顺利完成所有化疗周期。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 结语：三药安全用药提示 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #eaf6fa 0%, #f9fafb 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 结语：用药安全要牢记 📝\u003C/h2>\n    \u003Cdiv class=\"drug-summary-block\">\n      \u003Cspan class=\"emoji\">📎\u003C/span>\n      综合来看，紫杉醇、卡铂和贝伐珠单抗在化疗和靶向治疗中作用明确，但用药时要严格控制剂量、注意间隔、密切监测身体反应。最关键的有这么两点：\n      \u003Col>\n        \u003Cli>用药周期和剂量切勿擅自变更——所有调整需由医师评估并执行。\u003C/li>\n        \u003Cli>出现不适反应及时就医，不可靠“硬扛”或自购对症药自行处理。\u003C/li>\n      \u003C/ol>\n      用药期间建议使用专属药品记录表做好单次剂量、总疗程等信息的归档，避免遗忘。遇到任何疑问，务必第一时间咨询主治医生或药师。安全用药，关乎每一次健康的迈进。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 11 主要参考文献 -->\n  \u003Csection class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fcfb 0%, #e3f4f7 100%);\">\n    \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献 📚\u003C/h2>\n    \u003Cul class=\"drug-reference-list\">\n      \u003Cli>\n        McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., ... & Alberts, D. S. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 334(1), 1-6.\n      \u003C/li>\n      \u003Cli>\n        Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., ... & Ozols, R. F. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. \u003Ci>Journal of Clinical Oncology\u003C/i>, 27(9), 1419-1425.\n      \u003C/li>\n      \u003Cli>\n        Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., ... & Gynecologic Oncology Group. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 365(26), 2473-2483.\n      \u003C/li>\n      \u003Cli>\n        National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Ovarian Cancer (Version 2.2023).\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.drug-material-container {\n  max-width: 820px;\n  margin: 30px auto;\n  background: #fff;\n  border-radius: 18px;\n  box-shadow: 0 6px 22px 0 rgba(50, 80, 140, .10);\n  font-family: \"PingFang SC\", \"Helvetica Neue\", Arial, \"Microsoft YaHei\", sans-serif;\n  color: #232528;\n  padding: 28px 24px;\n  box-sizing: border-box;\n  line-height: 2;\n}\n.drug-material-title {\n  text-align: center;\n  font-size: 2.3em;\n  color: #2c497a;\n  font-weight: bold;\n  margin-bottom: 18px;\n  letter-spacing: 1.5px;\n}\n.drug-material-summary {\n  background: rgba(244, 247, 255, 0.48);\n  border-left: 5px solid #7cb6e1;\n  padding: 18px 30px 15px 40px;\n  margin-bottom: 26px;\n  font-size: 1.07em;\n}\n.emoji {\n  font-size: 1.3em;\n  vertical-align: middle;\n  margin-right: 8px;\n}\n.drug-section {\n  margin: 28px 0 30px 0;\n  padding: 18px 24px 18px 22px;\n  border-radius: 13px;\n  position: relative;\n  background-size: cover;\n  background-repeat: no-repeat;\n  min-height: 65px;\n  box-sizing: border-box;\n  transition: box-shadow .18s;\n}\n.drug-section-title {\n  font-size: 1.55em;\n  color: #245878;\n  font-weight: 600;\n  margin-bottom: 10px;\n  letter-spacing: .9px;\n  background: rgba(140, 174, 211, .13);\n  border-radius: 7px;\n  padding: 6px 13px 6px 14px;\n  display: inline-block;\n}\n.drug-point-list {\n  margin: 0 0 0 0;\n  padding-left: 24px;\n  font-size: 1.07em;\n}\n.drug-point-list li {\n  margin-bottom: 13px;\n  list-style-type: disc;\n}\n.drug-highlight {\n  color: #4190d1;\n  font-weight: bold;\n}\n.drug-tip {\n  margin: 18px 0 0 0;\n  background: #f6fafd;\n  border-left: 4px solid #88c0e7;\n  border-radius: 8px;\n  padding: 10px 18px 9px 16px;\n  font-size: 1.05em;\n  color: #375662;\n}\n.drug-summary-block {\n  background: #f5f8fca1;\n  border-left: 4px solid #aed687;\n  border-radius: 7px;\n  padding: 13px 26px;\n  font-size: 1.07em;\n  margin-top: 14px;\n  color: #2f433c;\n}\n.drug-reference-list {\n  font-size: .99em;\n  margin-top: 12px;\n  margin-bottom: 10px;\n  padding-left: 29px;\n}\n.drug-reference-list li {\n  margin-bottom: 13px;\n  color: #4b5274;\n  word-break: break-all;\n  font-size: 1em;\n  line-height: 1.7;\n}\n@media (max-width: 600px) {\n  .drug-material-container {\n    padding: 7px 3% 13px 3%;\n  }\n  .drug-section {\n    padding: 15px 3% 10px 3%;\n  }\n  .drug-section-title {\n    font-size: 1.08em;\n    padding: 5px 7px 5px 9px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"drug-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-material-title\" style=\"c",453,"2025-07-14 15:27:46","卵巢癌, 紫杉醇, 卡铂, 贝伐珠单抗, 化疗药物, 不良反应, 用药注意, 安全用药","本文深入解析卵巢癌复发的三种主要治疗药物：紫杉醇、卡铂和贝伐珠单抗，涵盖成分、用法、禁忌及副作用管理，助力患者安全用药并提升治疗效果。","2025-07-15 14:08:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]